Overview

A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

This is a single-center, open-lable, non-comparative, prospective, phase Ⅱ efficacy and safety study. Eligible patients are enrolled in a single group. The investigators propose to determine the efficacy and safety of low-dose metronomic chemotherapy with Etoposide/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes.

Phase:

Phase 2

Details

Lead Sponsor:

Tao OUYANG

Treatments:

Capecitabine
Etoposide
Etoposide phosphate
Taxane